1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. Keeping that in mind, here is one stock where you should be greedy instead of fearful and two facing legitimate challenges.

Two Stocks to Sell:

Avnet (AVT)

Consensus Price Target: $89 (-4.1% implied return)

With a century-long history of adapting to technological evolution, Avnet (NASDAQ:AVT) is a global electronic components distributor that connects manufacturers of semiconductors and other electronic parts with businesses that need these components.

Why Are We Hesitant About AVT?

1. Sales were flat over the last two years, indicating it’s failed to expand this cycle
2. Performance over the past two years shows each sale was less profitable, as its earnings per share fell by 17.7% annually
3. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital

Avnet’s stock price of $92.80 implies a valuation ratio of 11.6x forward P/E. If you’re considering AVT for your portfolio, see our FREE research report to learn more.

BNY (BNY)

Consensus Price Target: $142.85 (0.1% implied return)

Tracing its roots back to 1784 when it was founded by Alexander Hamilton, BNY (NYSE:BNY) is a global financial institution that provides asset servicing, wealth management, and investment services to institutions, corporations, and high-net-worth individuals.

Why Does BNY Fall Short?

1. The company has faced growth challenges as its 5.7% annual revenue increases over the last five years fell short of other financials companies
2. Large asset base makes it harder to grow tangible book value per share quickly, and its annual tangible book value per share growth of 4% over the last five years was below our standards for the financials sector
3. Low return on equity reflects management’s struggle to allocate funds effectively

BNY is trading at $142.77 per share, or 16.2x forward P/E. Check out our free in-depth research report to learn more about why BNY doesn’t pass our bar.

One Stock to Watch:

Elevance Health (ELV)

Consensus Price Target: $415.81 (3.6% implied return)

Formerly known as Anthem until its 2022 rebranding, Elevance Health (NYSE:ELV) is one of America's largest health insurers, serving approximately 47 million medical members through its network-based managed care plans.

Why Are We Fans of ELV?

1. 9.9% annual revenue growth over the last five years was better than the sector average, highlighting the value of its products and services
2. Unparalleled scale of $198.3 billion in revenue enables it to spread administrative costs across a larger membership base
3. Industry-leading 26.5% return on capital demonstrates management’s skill in finding high-return investments

At $401.50 per share, Elevance Health trades at 15.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.